Horizon Therapeutics Reports Topline Data From Phase 3 Clinical Trial (OPTIC-J) In Japan Evaluating TEPEZZA (teprotumumab-trbw) For Treatment Of Active Thyroid Eye Disease (TED)
Portfolio Pulse from Benzinga Newsdesk
Horizon Therapeutics reports positive topline data from Phase 3 clinical trial (OPTIC-J) in Japan for TEPEZZA (teprotumumab-trbw) in treating active thyroid eye disease (TED). At week 24, 89% of patients treated with TEPEZZA showed clinically meaningful improvement compared to 11% receiving placebo.
June 22, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Horizon Therapeutics' TEPEZZA demonstrated positive results in a Phase 3 clinical trial for treating active thyroid eye disease, potentially leading to increased demand and revenue for the company.
The positive results from the Phase 3 clinical trial of TEPEZZA indicate that the drug is effective in treating active thyroid eye disease. This could lead to increased demand for the drug, resulting in higher revenues for Horizon Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100